Home/Pipeline/PLX‑PAD

PLX‑PAD

Knee Osteoarthritis

Phase 3Active

Key Facts

Indication

Knee Osteoarthritis

Phase

Phase 3

Status

Active

Company

Pluri, Pluri, Pluri

About Pluri

Pluri leverages a proprietary 3D cell‑expansion platform to deliver scalable, off‑the‑shelf placental cell therapies and cultivated food solutions.

View full company profile

About Pluri

Pluri leverages a proprietary 3D cell‑expansion platform to deliver scalable, off‑the‑shelf placental cell therapies and cultivated food solutions.

View full company profile

About Pluri

Pluri leverages a proprietary 3D cell‑expansion platform to deliver scalable, off‑the‑shelf placental cell therapies and cultivated food solutions.

View full company profile

Therapeutic Areas

Regenerative Medicine Orthopedics Vascular Medicine

Other Knee Osteoarthritis Drugs

Drug	Company	Phase	Status
Progenza	Cambium Bio	Phase 1/2a	Active
MAG200	Magellan	Phase 3	Active
MUTI™ Knee Replacement	Meril	Commercial	Active
DUROLANE	Bioventus	Commercial	Active
XSTEM	Xintela	Phase I/IIa	Completed (Results Reported)
Stempeucel®	Stempeutics Research	Commercial	Approved
Lipogems System for Knee Osteoarthritis	Lipogems International	Phase 3	Active
Signature Cord Prime™	Arugula Sciences	Phase 1	Active
Knee Osteoarthritis Study	Arizona Research Center	Not Specified	Active - Enrolling
4P004	4Moving Biotech	Phase 2a	Active
Lorecivivint (inferred)	Biosplice Therapeutics	Phase 3	Active
Regenerative Cell Therapy for Osteoarthritis	InGeneron	Phase 3	Active